
Novartis To Present New Data At AAN, Including Seven-Year Disability Outcomes And Safety Analysis Of Kesimpta® In People ...
(MENAFN- PR Newswire) Long-term disability and safety data from ALITHIOS open-label extension study on continuous treatment with Kesimpta vs. later switch from teriflunomide in relapsing multiple sclerosis (RMS) patients to be presented Additional …